207 related articles for article (PubMed ID: 37467793)
1. The kynurenine pathway in major depressive disorder under different disease states: A systematic review and meta-analysis.
Ou W; Chen Y; Ju Y; Ma M; Qin Y; Bi Y; Liao M; Liu B; Liu J; Zhang Y; Li L
J Affect Disord; 2023 Oct; 339():624-632. PubMed ID: 37467793
[TBL] [Abstract][Full Text] [Related]
2. Cross-sectional relationship between kynurenine pathway metabolites and cognitive function in major depressive disorder.
Zhou Y; Zheng W; Liu W; Wang C; Zhan Y; Li H; Chen L; Ning Y
Psychoneuroendocrinology; 2019 Mar; 101():72-79. PubMed ID: 30419374
[TBL] [Abstract][Full Text] [Related]
3. Altered tryptophan catabolite concentrations in major depressive disorder and associated changes in hippocampal subfield volumes.
Doolin K; Allers KA; Pleiner S; Liesener A; Farrell C; Tozzi L; O'Hanlon E; Roddy D; Frodl T; Harkin A; O'Keane V
Psychoneuroendocrinology; 2018 Sep; 95():8-17. PubMed ID: 29787958
[TBL] [Abstract][Full Text] [Related]
4. Kynurenine pathway in depression: A systematic review and meta-analysis.
Ogyu K; Kubo K; Noda Y; Iwata Y; Tsugawa S; Omura Y; Wada M; Tarumi R; Plitman E; Moriguchi S; Miyazaki T; Uchida H; Graff-Guerrero A; Mimura M; Nakajima S
Neurosci Biobehav Rev; 2018 Jul; 90():16-25. PubMed ID: 29608993
[TBL] [Abstract][Full Text] [Related]
5. Relationship between neurotoxic kynurenine metabolites and reductions in right medial prefrontal cortical thickness in major depressive disorder.
Meier TB; Drevets WC; Wurfel BE; Ford BN; Morris HM; Victor TA; Bodurka J; Teague TK; Dantzer R; Savitz J
Brain Behav Immun; 2016 Mar; 53():39-48. PubMed ID: 26546831
[TBL] [Abstract][Full Text] [Related]
6. Reduction of kynurenic acid to quinolinic acid ratio in both the depressed and remitted phases of major depressive disorder.
Savitz J; Drevets WC; Wurfel BE; Ford BN; Bellgowan PS; Victor TA; Bodurka J; Teague TK; Dantzer R
Brain Behav Immun; 2015 May; 46():55-9. PubMed ID: 25686798
[TBL] [Abstract][Full Text] [Related]
7. Relationship between the tryptophan-kynurenine pathway and painful physical symptoms in patients with major depressive disorder.
Yun Y; Zhang Q; Zhao W; Ma T; Fan H; Bai L; Ma B; Qi S; Wang Z; An H; Yang F
J Psychosom Res; 2022 Dec; 163():111069. PubMed ID: 36335711
[TBL] [Abstract][Full Text] [Related]
8. C-Reactive protein and the kynurenic acid to quinolinic acid ratio are independently associated with white matter integrity in major depressive disorder.
Zheng H; Teague TK; Yeh FC; Burrows K; Figueroa-Hall LK; Aupperle RL; Khalsa SS; Paulus MP; Savitz J
Brain Behav Immun; 2022 Oct; 105():180-189. PubMed ID: 35853557
[TBL] [Abstract][Full Text] [Related]
9. Tryptophan metabolite concentrations in depressed patients before and after electroconvulsive therapy.
Ryan KM; Allers KA; McLoughlin DM; Harkin A
Brain Behav Immun; 2020 Jan; 83():153-162. PubMed ID: 31606477
[TBL] [Abstract][Full Text] [Related]
10. Kynurenine pathway metabolites are associated with hippocampal activity during autobiographical memory recall in patients with depression.
Young KD; Drevets WC; Dantzer R; Teague TK; Bodurka J; Savitz J
Brain Behav Immun; 2016 Aug; 56():335-42. PubMed ID: 27091600
[TBL] [Abstract][Full Text] [Related]
11. The relationship between plasma serotonin and kynurenine pathway metabolite levels and the treatment response to escitalopram and desvenlafaxine.
Sun Y; Drevets W; Turecki G; Li QS
Brain Behav Immun; 2020 Jul; 87():404-412. PubMed ID: 31978524
[TBL] [Abstract][Full Text] [Related]
12. A mood state-specific interaction between kynurenine metabolism and inflammation is present in bipolar disorder.
van den Ameele S; van Nuijs AL; Lai FY; Schuermans J; Verkerk R; van Diermen L; Coppens V; Fransen E; de Boer P; Timmers M; Sabbe B; Morrens M
Bipolar Disord; 2020 Feb; 22(1):59-69. PubMed ID: 31398273
[TBL] [Abstract][Full Text] [Related]
13. Antidepressant effect of repeated ketamine administration on kynurenine pathway metabolites in patients with unipolar and bipolar depression.
Zhou Y; Zheng W; Liu W; Wang C; Zhan Y; Li H; Chen L; Li M; Ning Y
Brain Behav Immun; 2018 Nov; 74():205-212. PubMed ID: 30213652
[TBL] [Abstract][Full Text] [Related]
14. Increased breakdown of kynurenine towards its neurotoxic branch in bipolar disorder.
Birner A; Platzer M; Bengesser SA; Dalkner N; Fellendorf FT; Queissner R; Pilz R; Rauch P; Maget A; Hamm C; Herzog-Eberhard S; Mangge H; Fuchs D; Moll N; Zelzer S; Schütze G; Schwarz M; Reininghaus B; Kapfhammer HP; Reininghaus EZ
PLoS One; 2017; 12(2):e0172699. PubMed ID: 28241062
[TBL] [Abstract][Full Text] [Related]
15. The Metabolic Factor Kynurenic Acid of Kynurenine Pathway Predicts Major Depressive Disorder.
Liu H; Ding L; Zhang H; Mellor D; Wu H; Zhao D; Wu C; Lin Z; Yuan J; Peng D
Front Psychiatry; 2018; 9():552. PubMed ID: 30510519
[No Abstract] [Full Text] [Related]
16. Kynurenic acid is reduced in females and oral contraceptive users: Implications for depression.
Meier TB; Drevets WC; Teague TK; Wurfel BE; Mueller SC; Bodurka J; Dantzer R; Savitz J
Brain Behav Immun; 2018 Jan; 67():59-64. PubMed ID: 28867283
[TBL] [Abstract][Full Text] [Related]
17. The role of the kynurenine pathway and quinolinic acid in adolescent major depressive disorder.
Öztürk M; Yalın Sapmaz Ş; Kandemir H; Taneli F; Aydemir Ö
Int J Clin Pract; 2021 Apr; 75(4):e13739. PubMed ID: 32997876
[TBL] [Abstract][Full Text] [Related]
18. Psychological outcomes of COVID-19 survivors at sixth months after diagnose: the role of kynurenine pathway metabolites in depression, anxiety, and stress.
Kucukkarapinar M; Yay-Pence A; Yildiz Y; Buyukkoruk M; Yaz-Aydin G; Deveci-Bulut TS; Gulbahar O; Senol E; Candansayar S
J Neural Transm (Vienna); 2022 Aug; 129(8):1077-1089. PubMed ID: 35796878
[TBL] [Abstract][Full Text] [Related]
19. Behavioral activation therapy for depression is associated with a reduction in the concentration of circulating quinolinic acid.
Savitz J; Ford BN; Yeh HW; Akeman E; Cosgrove K; Clausen AN; Martell C; Kirlic N; Santiago J; Teague TK; Irwin MR; Paulus MP; Aupperle RL
Psychol Med; 2022 Oct; 52(13):2500-2509. PubMed ID: 33234171
[TBL] [Abstract][Full Text] [Related]
20. The kynurenine pathway in major depressive disorder, bipolar disorder, and schizophrenia: a systematic review and meta-analysis of cerebrospinal fluid studies.
Inam ME; Fernandes BS; Salagre E; Grande I; Vieta E; Quevedo J; Zhao Z
Braz J Psychiatry; 2023 May; 45(4):343-55. PubMed ID: 37127280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
